DDW’s Megan Thomas rounds up highlights from Monday 16 April at AACR 2023, from promising trial results for colorectal cancer patients to updates on Biden’s Cancer Moonshot initiative. Clinical announcements Data on colorectal cancer patients with African ancestry Today, data presented at the AACR Annual Meeting showed that genomic… Read More
DDW’s Megan Thomas rounds up highlights from Sunday 16 April at AACR 2023, from promising trial results for a personalised mRNA-based cancer vaccine to winners of lifetime achievement awards. Opening plenary session Sunday’s opening plenary session borrowed its name from the Annual Meeting theme, “Advancing the Frontiers of Cancer Science… Read More
The American Association for Cancer Research (AACR) Annual Meeting is taking place at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023. As the theme, Advancing the Frontiers of Cancer Science and Medicine, suggests, a number of announcements, results and presentations will take place… Read More
Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer. Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated,… Read More
Listen to this article on the DDW Podcast: Following his recent OBE, Diana Spencer speaks to Dr Harren Jhoti about his career, the UK life sciences sector, fragment-based drug discovery and what the future holds for the industry. At the end of 2022, Astex Pharmaceuticals co-founder, President and CEO Dr Harren… Read More
In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 20301. The pharmaceutical firm also provided promising updates on mRNA-4157/V940, which targets different tumour types, at Moderna’s Vaccines Day on 24 March 20232. The… Read More
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab). The drug is approved for use within NHS England and NHS Wales and as add-on maintenance therapy in adult and adolescent patients, 12 years and older, with severe asthma… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The headlines this week have revealed a high level of clinical trial activity taking place… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The headlines this week have revealed a high level of clinical trial activity taking place… Read More
Ahead of attending the American Association for Cancer Research (AACR) annual meeting from 14-19 April, 2023 at the Orange County Convention Center in Orlando, Florida, DDW’s Megan Thomas outlines what to expect from the event. Programme highlights The topic tracks include everything from clinical trials, drug development, immunology and bioinformatics,… Read More
This is the latest episode of the free DDW podcast, “Data integrity and the value of the cloud”. It covers two articles written for the exclusive DDW & SLAS2022 supplement published in Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “The concept of data… Read More
This is the latest episode of the free DDW narrated podcast, “Data integrity and the value of the cloud”. It covers two articles written for the exclusive DDW & SLAS2022 supplement published in Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “The concept of data integrity”… Read More
Granular Therapeutics, a UK-based biotech company specialising in precision biologic therapies for treating mast cell driven disorders, announced clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies. Granular Therapeutics has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares… Read More
CureSearch for Children’s Cancer, a national non-profit with a mission to end childhood cancer by driving targeted and innovative research in an accelerated time frame, will fund a Phase I clinical trial to bring new therapies to paediatric brain cancer patients, including those with limited or no treatment options. Read More
Sequana Medical, a company treating fluid overload in liver disease, heart failure and cancer, has announced positive results from its Phase I single-centre, single-arm, single-dose trial (CHIHUAHUA) with its second-generation DSR product (DSR 2.0). The purpose of the trial was to evaluate the safety and tolerability profile… Read More
Galapagos and NovAliX have entered a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organisation. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and… Read More
